These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 9550246)
21. Risperidone in treatment-refractory schizophrenia. Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947 [TBL] [Abstract][Full Text] [Related]
22. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427 [TBL] [Abstract][Full Text] [Related]
23. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461 [TBL] [Abstract][Full Text] [Related]
24. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
25. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972 [TBL] [Abstract][Full Text] [Related]
26. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763 [TBL] [Abstract][Full Text] [Related]
27. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566 [TBL] [Abstract][Full Text] [Related]
28. The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study. Di Lorenzo R; Fiorini F; Santachiara S Psychopharmacol Bull; 2010; 43(1):39-52. PubMed ID: 20581799 [TBL] [Abstract][Full Text] [Related]
30. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772 [TBL] [Abstract][Full Text] [Related]
31. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G; Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797 [TBL] [Abstract][Full Text] [Related]
32. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Henderson DC; Goff DC J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446 [TBL] [Abstract][Full Text] [Related]
33. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Li H; Rui Q; Ning X; Xu H; Gu N Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787 [TBL] [Abstract][Full Text] [Related]
34. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382 [TBL] [Abstract][Full Text] [Related]
35. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348 [TBL] [Abstract][Full Text] [Related]
36. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995 [TBL] [Abstract][Full Text] [Related]
37. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. Grcevich SJ; Findling RL; Rowane WA; Friedman L; Schulz SC J Child Adolesc Psychopharmacol; 1996; 6(4):251-7. PubMed ID: 9231318 [TBL] [Abstract][Full Text] [Related]